Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The all-cause mortality benefit had been in question after Attruby missed this secondary endpoint in ATTRibute-CM
Pfizer is building a trial that can answer, within a year or two, whether monthly is a clinically defensible default schedule or a niche convenience option
The inhibitory effects of IGF-1 on IL-1-induced NF-B activation are partially mediated by inhibiting the Src/PI3K/AKT pathway [29]
144 GLP-1 RAs or a dual GLP-1/GIP RA as perpetrator drugs in combination with a victim drug, a number of clinical trials have been conducted to evaluate DDI potentials (Table 4 and Table 5)
US$ 20.35
US$ 27.17
US$ 28.09
